AptarGroup, Inc. (ATR) Stock Price & Analysis
AptarGroup, Inc. (ATR) closed at USD 128.1 on Thursday, October 22, 2026, up 1.97% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 125.63; the Oct 22, 2026 session ranged USD 125.93–128.72 on volume of 426,358 shares. Market capitalization is $8.14B, with a 52-week range of USD 103.23–146.91 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:36 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ATR.md
Key facts (ATR)
- Last four reported quarters (through Jun 30, 2026): revenue $3.93B, net income $363M (9.2% margin), free cash flow $310M (SEC filings).
- Valuation: P/E 22.5x (avg 26.1x at the last 3 fiscal year-ends), EV/EBITDA 11.8x, net debt $1.14B.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (9 analysts), mean target USD 162.25 (range 135–220).
- Total return with dividends: 1Y -0.9% vs S&P 500 +14.9%; 5Y +7.1% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 1.47, revenue estimate $981M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ATR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.23B | $3.32B | $3.49B | $3.58B | $3.78B | $3.93B |
| Operating income | $347M | $379M | $404M | $496M | $501M | $477M |
| Net income | $244M | $239M | $284M | $375M | $393M | $363M |
| EPS (diluted) | $3.61 | $3.59 | $4.25 | $5.53 | $5.89 | — |
| Free cash flow | $55.5M | $168M | $263M | $367M | $300M | $310M |
| Operating margin | 10.8% | 11.4% | 11.6% | 13.9% | 13.3% | 12.1% |
| Net margin | 7.6% | 7.2% | 8.2% | 10.5% | 10.4% | 9.2% |
| Revenue growth | +10.2% | +2.9% | +5.0% | +2.7% | +5.4% | — |
| Cash + short-term investments | $124M | $142M | $224M | $226M | $410M | — |
| Total debt | $1.05B | $1.17B | $1.06B | $864M | $1.32B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ATR)
P/E 22.5x · P/S 2.1x · EV/EBITDA 11.8x · EV/Sales 2.4x · P/FCF 26.2x · P/B 3.1x · FCF yield 3.81% · Earnings yield 4.45% · Dividend yield (paid, TTM) 1.51% · Buyback yield (TTM) 4.48% · Net debt $1.14B · EV $9.28B
P/E at fiscal year-ends: Dec 2025 20.7x, Dec 2024 28.4x, Dec 2023 29.1x.
Analysts (ATR)
Consensus Buy (mean 2.00 on a 1–5 scale), 9 analysts; mean target USD 162.25 (low 135, high 220).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-09 | UBS | Initiated | Neutral | $135 |
| 2026-08-03 | Wells Fargo | Target raised | Overweight | $145 → $155 |
Total return (dividends reinvested) (ATR)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -0.9% | +7.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -0.9% | +1.4% |
| Volatility (annualized) | 25.0% | 22.6% |
| Max drawdown | -22.9% (Feb 2026→Jun 2026) | -34.2% (Nov 2024→Jun 2026) |
ATR revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Pharma | $458.3M | 44.6% | +3.5% |
| Beauty | $377.4M | 36.8% | +10.3% |
| Closures | $202.6M | 19.7% | +6.5% |
| Total revenue | $1.03B | 100% | — |
ATR revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Europe | $521.0M | 50.8% | +9.5% |
| Domestic | $292.0M | 28.4% | -5.7% |
| Asia | $128.4M | 12.5% | +23.3% |
| Latin America | $85.1M | 8.3% | +11.7% |
| Total revenue | $1.03B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ATR company outlook (results filed Jul 30, 2026)
- “Regarding Aptar's outlook, Tanda stated, "In alignment with Gael Touya, who will assume the role of CEO on September 1, we enter the third quarter with confidence.”
- “Supported by our innovation pipeline and strong market positions, these trends support our outlook for the third quarter." 2 Aptar currently expects adjusted earnings per share for the third quarter of 2026 to be in the range of $1.45 to $1.53.”
- “This guidance assumes an effective tax rate range of 22.5% to 24.5%.”
- “The earnings per share guidance range is assuming a 1.14 Euro to USD exchange rate.”
Quoted word-for-word from the SEC 8-K results press release.
ATR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.47 | $1.46 | +0.6% | $980.8M | 8 |
| Next quarter (ends Dec 2026) | $1.41 | $1.48 | -5.0% | $976.8M | 8 |
| Current fiscal year (ends Dec 2026) | $5.49 | $5.49 | +0.2% | $3.97B | 8 |
| Next fiscal year (ends Dec 2027) | $6.18 | $6.25 | -1.2% | $4.11B | 8 |
Key Statistics (as of October 23, 2026 at 10:36 UTC)
| Price | USD 128.1 |
|---|---|
| Change | ▲ 1.97% (up) |
| Previous Close | USD 125.63 |
| Open | USD 125.66 |
| Day Range | USD 125.93 – 128.72 |
| 52-Week Range | USD 103.23 – 146.91 |
| Volume | 426,358 shares |
| Market Cap | $8.14B |
| Exchange | NYQ |
Technical Analysis (ATR)
Nexqual's technical model rates ATR "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 10:36 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.11 (neutral) |
| vs SMA50 | Above (USD 126.24) |
| MACD | 0.09 (positive) |
Analyst Ratings (ATR)
Wall Street analysts rate ATR "Buy" based on 9 analysts, with a mean price target of USD 162.25 (range USD 135–220), per Nexqual as of October 23, 2026 at 10:36 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 162.25 |
| High Target | USD 220 |
| Low Target | USD 135 |
| Buy / Hold / Sell | 7 / 2 / 0 |
Earnings (ATR)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 1.47 |
| Revenue Estimate | $980.76M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.42 vs est 1.35 ▲ beat |
| 2026-03-31 | USD 1.19 vs est 1.15 ▲ beat |
| 2025-12-31 | USD 1.25 vs est 1.23 ▲ beat |
| 2025-09-30 | USD 1.62 vs est 1.57 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:36 UTC.
Financials & Fundamentals (ATR)
| Total Revenue | $3.93B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +6.30% |
| Gross Margin | +36.07% |
| Operating Margin | +12.49% |
| Profit Margin | +9.22% |
| ROE | +13.46% |
| Debt / Equity | 0.53 |
| Current Ratio | 1.61 |
| Total Cash | $197.27M |
| Total Debt | $1.41B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $310.39M (7.9% of revenue) |
Source: Nexqual, October 23, 2026 at 10:36 UTC.
Financial Health Score (ATR)
Nexqual rates AptarGroup, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:36 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 36%, operating 12% (last 12 months) |
| Balance Sheet | Solid — $197M cash and investments vs $1.34B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $310M (last 4 quarters to Jun 2026, SEC), 8% margin |
| Efficiency | Mixed — ROE 13%, ROA 6.1% |
Ownership (ATR)
| Insider Ownership | +0.86% |
|---|---|
| Institutional Ownership | +97.94% |
| Shares Outstanding | 63.58M |
| Float | 62.97M |
| Short % of Float | +3.73% |
Source: Nexqual, October 23, 2026 at 10:36 UTC.
Leadership (ATR)
AptarGroup, Inc. is led by Gael Touya, CEO, President & Director, per Nexqual as of October 23, 2026 at 10:36 UTC.
| CEO, President & Director | Gael Touya |
|---|---|
| Executive VP & CFO | Vanessa Kanu |
| Director & Advisor | Stephan B. Tanda |
| President of Aptar Beauty | Marc Prieur |
| Executive VP of Strategic Group Development & President of Aptar Asia | Xiangwei Gong |
Major Backers & Investors (ATR)
Notable institutional backers of AptarGroup, Inc. include State Farm Mutual Automobile Insurance Co, Morgan Stanley, Victory Capital Management Inc., according to Nexqual as of October 23, 2026 at 10:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| State Farm Mutual Automobile Insurance Co | 7.46% |
| Morgan Stanley | 5.54% |
| Victory Capital Management Inc. | 4.02% |
| Victory Portfolios-Victory Sycamore Established Value Fund | 2.92% |
| Eaton Vance Growth Trust-Eaton Vance Atlanta Capital SMID-Cap Fund | 2.73% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 10.27% |
| BlackRock | 9.65% |
| State Street | 4.5% |
| Geode Capital | 2.75% |
| Dimensional Fund Advisors | 2.74% |
Source: Nexqual, October 23, 2026 at 10:36 UTC.
From AptarGroup, Inc.'s Latest SEC 10-K Filing (filed 2026-02-06)
Key Strengths & Strategy (as disclosed to the SEC)
- Leveraging our proprietary polymer-based technologies, we enable enhanced mitigation of impurities and degradation, product stability, shelf life, and performance across medical device, drug delivery, and selected food protection applications.
- While we expect that these types of new products will come to market in the future, it is difficult to estimate when, as the rigors of pharmaceutical regulations affect the timing of product introductions by our pharmaceutical customers that use our proprietary drug delivery systems.
- We have developed a multi-dose dispensing device suitable for ophthalmic formulations.
- Although Europe represents the largest region for us in terms of sales, our beauty and pharmaceutical customers often export their finished products using our technology around the world for consumption.
Partnerships
- Historically, the environmental impact of these processes has been minimal, and we collaborate with local permitting authorities to ensure we operate responsibly.
Legal & Regulatory Risks (Item 1A, quoted)
- Risks Related to Financial, Legal and Regulatory Matters
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BLCO | Bausch + Lomb Corporation | USD 17.43 | ▲ 1.46% |
| ALGN | Align Technology, Inc. | USD 155.51 | ▲ 2.74% |
| RGEN | Repligen Corporation | USD 178.71 | ▼ 0.72% |
| AVTR | Avantor, Inc. | USD 17.15 | ▼ 0.64% |
| COO | The Cooper Companies, Inc. | USD 61.65 | ▲ 4.54% |
| TFX | Teleflex Incorporated | USD 136.58 | ▲ 4.74% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:36 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt